U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT07576959) titled 'Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication' on April 27.
Brief Summary: This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.
Study Start Date: April 08
Study Type: INTERVENTIONAL
Condition:
HELICOBACTE...